Scientific Sessions/Tracks

Track 1: Drug Discovery and Innovative Drug Discovery

Drug discovery is the process through which potential new medicines are recognized and comprises an extensive range of scientific disciplines, including biology, chemistry and pharmacology. The integration of pharmacodynamics and pharmacokinetic parameters in non-clinical pharmacology studies is a key characteristic in drug discovery for efficacy and safety assessment, in the particular for the translation from the non-clinical to  clinical field and process of drug discovery include  the identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy where as modern drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity, efficacy/potency, metabolic stability, and oral bioavailability. The "final product" of drug discovery is a patent on the potential drug.

The global market for drug discovery technologies and products reached $38.4 billion in 2011. It is expected to expand to $41.4 billion in 2012 and to $79.0 billion in 2017, CAGR of 13.8% between 2012 - 2017.

Track 2: Drug Discovery and Development

The pharmaceutical sector, a foundation of the healthcare sector, is undergoing extensive change, essentially caused by lower output of new medicines from research and development (R&D) laboratories, drug pricing pressures, stricter regulatory environments and the overall current economic recession. This sorts strains of all pharmaceutical firms to find better ways to raise their yield of new drugs, complete improvement, to equally treat patients and happen their shareholders assumption.

Track 3: Nanotechnology in Drug Discovery

Nanotechnology is a study of science and technology which targets to regulate matter at the atomic, molecular, and macromolecular level. New nanotechnologies could bring intense increases in the sensitivity of detection technology for research and diagnostic applications, improved imaging technologies, greater selectivity for drug delivery, and detailed insight into biological mechanisms and systems. Nano biosensors and Nano biochips are used to develop drug discovery and development. Nano scale assays can subsidize substantially to cost-saving in screening promotions. The practise of Nano scale delivery vehicles prominent to the discovery of optimally safe in talling to effective drug candidates, current and promising applications of Nano medicine include, drug delivery, in vitro diagnostics, in vivo imaging, therapy techniques, biomaterials, and tissue engineering .As recognition of the importance of this moving field, it is estimated that the global market of Nano scale applications in medical field might grow to $70 - $160 bn.            

According to BCC Research, the global market for nanoparticles in life sciences is assessed at over $29.6 bn for 2014. This market is assessed to raise to more than $79.8 bn by 2019, to record a strong CAGR of 22%.

Track 4: Drug Discovery in Preclinical Research

The chief impartial of pre-clinical studies is to define the safe dose for first-in-man study and assess a product's safety profile.  Pre-clinical development also recognised as pre-clinical studies and non-clinical studies .In the drug development, preclinical development, is a phase study which prior to earlier clinical trials can begin, and during which important possibility, iterative testing and drug safety data is composed. Generally, only one in every 5,000 compounds that arrives drug discovery to the stage of pre-clinical development befits as an approved drug. These pre-clinical studies involve local toxicity studies such as acute, sub-acute, chronic toxicity studies and systemic toxicity studies such as genotoxicity and carcinogenicity studies.

Track 5: Clinical Trials and Regulatory Affairs

Clinical trials generate data on safety and efficacy. Such consequent biomedical or behavioural research studies on human participants are designed to answer specific questions about biomedical or behavioural interferences, including new treatments such as novel vaccines, drugs, dietary supplements, and medical devices. These trials produce data on safety and efficacy. The regulatory affairs outsourcing market has been segmented into five major service sections .Those sections include regulatory affairs, clinical trial applications and product registrations, regulatory writing and publishing, regulatory consulting and legal representation and others. The market sections have been broadly scheduled on the source of their usefulness, efficacy, and generated revenue and geographic revenue.          

The market size and estimate in USD million for every service type for the period from 2010 -2020, considering 2013 as basic year. This report also delivers the compounded annual growth rate (CAGR %) for each market segment for the forecast period from 2014- 2020.

Track 6: Drug designing and Molecular Modelling

Drug design, frequently called as rational drug design, is the resourceful process of discovering new medications based happening the knowledge of a biological target. The saying "drug design" is to also known as ligand design. This molecule design will bind tightly to its target. While design techniques for prediction of binding affinity are practically successful but there are many other properties, such as bioavailability, metabolic half-life, side effects, etc., that must be enhanced before a ligand can become a safe and efficacious drug. The normal cost of developing new drug molecules and the period taken to market them is high. Molecular modelling methods also known as Computational methods. These techniques can be utilized to speed up drug discovery process for earning new drug molecules. Reliant on the context and the rigor, the subject is often stated to as ‘molecular graphics’, ‘molecular visualizations’, ‘computational chemistry’, or ‘computational quantum chemistry’.

Track 7: Novel Therapeutics in Drug Designing

Nanotechnology is an evolving unparalleled technology. It has substantial use in the diagnosis and treatment of disease and is highly prospective towards to be used in foods, cosmetics and medical products. Nanoparticles assurance to increase in capability and complexity. They are used to enhance the pharmacokinetic and pharmacodynamics profiles of many drug molecules. Biodegradable nanoparticles are using in pharmaceutical formulations to release and transport the drug efficiently.

Track 8: Pulmonary Drug Discovery and Therapy

In the second half of 20^th century the accessibility of potential asthma drugs is increased. For the treatment of respiratory disease the drugs are delivered directly to the lungs thereby availability is convenient, portable delivery systems origins of inhalation therapy can be traced back to the early civilizations .This route of administration was unusual until recently. It was discovered that the large highly absorptive surface area of the lung can be used for systemic delivery of proteins such as insulin in the search for non-invasive delivery of biologics. New delivery systems with efficiency and reproducibility to match the high level and therapeutic constraints of biologics are currently in late stage clinical trials. Straight small molecular weight drugs previously administered by injection are tested through the inhalation route either to provide non-invasively rapid onset of action, or to improve the therapeutic ratio for drugs acting in the lung. Gene therapy of pulmonary disease is still in its initial stages but could deliver valuable solutions to currently unmet medical needs. The establishing of the new period is therefore likely to spectator development of many valuable therapeutic products provided by inhalation.

Track 9: Drug Metabolism and Drug Design

Pre-clinical metabolism & pharmacokinetic aspects are crucial in lead generation and optimization. The most important determinants of the pharmacokinetic profile of a drug are metabolism by the host organism. High metabolic charge regularly hints to poor bioavailability and high clearance. The development of active or toxic metabolites will have an impact on the pharmacological and toxicological outcomes and there will be also possible for drug-drug interactions with administered drugs due to inhibition and /or induction of drug metabolism pathways. Thereby, optimization of the metabolic liability and drug-drug interaction potential of the new chemical entities are certain of the greatest crucial steps during the drug discovery process. The rate and site of metabolism of new chemical entities by drug metabolizing enzymes are approachable to modulation by appropriate structural changes. In the same way, the potential for drug-drug interactions can also be lessened by appropriate structural modifications to the drug candidate. Yet, the optimization of the metabolic stability and drug-drug interaction potential during drug discovery stage has been mostly by empirical methods and by trial and error.

Track 10: Spectroscopy Methods in Drug Discovery

Different spectroscopic procedures are being used in drug discovery studies. There are inventive innovative efforts to put on several mass spectrometric techniques in early drug discovery, preclinical and clinical development, as well as in Phase 0 studies using Accelerator Mass Spectrometry. To examine the small bodies as well as greater molecules, life scientists increasing impart on methods like HPLC, HPTLC, LC-MS. Liquid chromatography-mass spectrometry (LC-MS). It is a systematic technique that couples high resolution chromatographic parting with sensitive and specific mass spectrometric detection and it comprises   high performance liquid chromatography (HPLC)-MS. It is perhaps the most powerful technique for pharmaceutical analysis. The applications of LC-MS in pharmaceutical analysis have been in drug metabolism studies, the analysis and identification of impurities and degradation products in pharmaceuticals and the isolation and characterization of potential drug substances from natural synthetic sources.

The International spectrometry business increased from $7.8 bn in 2011 to $8.5 bn through 2011-2012 and it is forecasted to reach $14.8 bn in 2017, at CAGR of 11.7% for the prognosis period of 2012 -2017.

Track 11: Medicinal Chemistry in Modern Drug Discovery

The modern drug discovery process is an overview to the development of new drugs. Now a days new biological targets, methodologies and advanced computing have enhanced modern drug discovery and have given medicinal chemistry a more thoughtful skill set and toolkit to hold the nuances  of disease pathophysiology. The medicinal chemistry related methodologies and a methodology in drug discovery improves the efficiency   in drug discovery and lessening attrition. In drug designing, structure-based drug design, and fragment –based drug design, natural product-based drug design, diversity-based drug design, and chemo genomics are applied.

Track 12: Pharmaceutical Biotechnology and Clinical Drug Evaluation

The introduction of biotechnology-derived pharmaceuticals for clinical use has frequently required for the application of unique approaches to evaluating their safety in preclinical studies. There is abundant assortment among these products, which comprise the gene and cellular therapies, monoclonal antibodies, human-derived recombinant regulatory proteins, blood products, and vaccines. There will be distinctive product issues for many of the biological therapies that may definite precise modifications to protocol design and may raise additional safety concerns. Clinical trials are observations which are finished in clinical research and are accompanied only after they have received health authority/ethics committee approval in the country where approval of the therapy is required. These authorities are liable for screening the risk/benefit ratio of the trial. Their approval does not mean that the therapy is 'safe' or effective, only that the trial may be conducted.

Track 13: Pharmaceutical and Biomedical Analysis

Pharmaceutical and biomedical analysis deals with the diversified features of analysis in the pharmaceutical, biomedical and clinical sciences, including developments in analytical methodology, i, computation and interpretation. It is obvious throughout healthcare, from diagnosis and analysis to treatment and recovery, and has entered the public integrity though the propagation of implantable medical devices, such as pacemakers and artificial hips, to more futuristic technologies such as stem cell engineering and the 3-D printing of biological organs.

 Track 14: Computational Molecular Biology

Computational Molecular Biology is a comparatively new science, with enormous growth since few years. Computational Biology is planned to afford a unique and in effect venue for the rapid publication of monographs, textbooks, edited collections, reference works, and lecture notes of the maximum quality. It deals with the key issues concerning analysis of genomes, sequences and structures. Bioinformatics is both  parasol term for the body of biological studies that use computer programming as part of their methodology, as well as a reference to specific analysis "pipelines" that are frequently used, mostly in the field of genomics.

Track 15: Pharmaceutical Research and Development

In discovery procedure comprises the initial stages of research, which are intended to recognize an investigational drug and perform primary tests in the lab. This first stage of the process takes   three to six years. By the end, investigators hope to identify a capable drug aspirant to further study in the lab and in animal models, and then in people. These developments offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used along with diagnostics, clinical trial protocols must be improved and increased.

Track 16: Computer Aided Drug Design (CADD)

Molecular mechanics is most commonly used to estimate the strength of the intermolecular interaction between the small molecule and its biological target. It can also be used to provide semi-quantitative prediction of the binding affinity. This method will be able to predict affinity before a compound is synthesized and hence only one compound needs to be synthesized. Computational methods have accelerated finding by decreasing the number of iterations required and must often provide novel structures.

The bio simulation market is forecasted to cross $2,108 Million to $1,035 Million through 2015-2020, growing at a 15.29% CAGR.

Market Analysis

The Ultimatum for drug discovery technologies in the region of North America also advances from high-income population, collectively promising healthy potential returns on investments owing to high approval to rate of new technologies.

Transparency Market Research (TMR) has recently published a research study on the global fragment-based drug discovery market and estimated it to report a CAGR of 14.40% during the period from 2015 to 2023. The market is projected to increase from a value of US$0.4 bn in 2014 to a value of US$1.2 bn by 2023.

GBI Research finds that the total drug discovery and development market size in the top seven Asian countries was estimated at $5.3 billion in 2011 and is forecast to reach $17.3 billion by the end of 2018.

The Middle-East & Africa market will be worth $ 402 million by the end of 2014 and is poised to reach $1.31 billion by 2020 at a CAGR of 26.63%

Revenue growth has been exceeded by investments in pharmaceutical R&D that have not increased the output of new medicines. Research-based pharmaceutical companies outsource R&D processes to CROs which offer integrated services across the life-sciences R&D value chain. Globalization in the clinical trial industry has led to an increased number of trials being conducted in emerging markets.